A clear Semaglutide research vial on a coloured plaster ledge, with botanicals beside it

About this compound

Semaglutide is a 31-residue acylated analogue of human GLP-1, carrying an AEEA-AEEA linker and a C18 fatty diacid side chain for albumin binding and extended half-life.

Studied in

  • GLP-1 receptor signalling
  • Glucose handling
  • Metabolic models

Compound identity

CompoundSemaglutide
CAS number910463-68-2
Molecular formulaC187H291N45O59
Molecular weight4,113.64 Da

Specifications

  • Purity method: HPLC
  • Appearance: Lyophilized powder
  • Solubility: Reconstitute per protocol; see Supplies for diluents.
  • We don't publish a purity percentage here — that figure is only meaningful tied to the lot you actually receive, so it lives on the lot certificate.

Metabolic

Semaglutide

A long-acting GLP-1 receptor agonist.

What the research targets

Studied in gut-hormone (GLP-1) receptor signalling models.

Research use only

Supplied to qualified professionals and institutions for laboratory research. Not a drug, supplement or cosmetic, and not for human or veterinary use. We publish no dosing or administration guidance of any kind.

Supply formats

Buy one, or a case of ten.

Single unit

One unit.

  • 5 mgVial

    SK-3053392-5-MG

    On verified account
  • 10 mgVial

    SK-3053392-10-MG

    On verified account

Case — 10-pack

10 of the same size, at the 10-pack price.

  • Case · 10 × 5 mg

    10-pack price — 10 × one unit, per vial.

    SK-3053392-C10-5-MG

    On verified account
  • Case · 10 × 10 mg

    10-pack price — 10 × one unit, per vial.

    SK-3053392-C10-10-MG

    On verified account

One-time verification of professional or institutional affiliation. No payment is taken on this site.

Compared with another compound

Where a study examined Semaglutide and another catalog compound in the same participants, the comparison page reports that trial — its population, its duration and its endpoint. Where no such study exists, it says so rather than comparing results across separate trials.